prikaz prve stranice dokumenta Učinak koronavirusnih cjepiva BNT162b2 i Ad26.CoV2.S na proupalne i koagulacijske pokazatelje
  Download
PDF 2.3 MB
doctoral thesis
Učinak koronavirusnih cjepiva BNT162b2 i Ad26.CoV2.S na proupalne i koagulacijske pokazatelje
Zagreb: University of Zagreb, School of Medicine, 2024. urn:nbn:hr:105:753928
Ivanko, Iva
University of Zagreb
School of Medicine

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Ivanko, I. (2024). Učinak koronavirusnih cjepiva BNT162b2 i Ad26.CoV2.S na proupalne i koagulacijske pokazatelje (Doctoral thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:753928

Ivanko, Iva. "Učinak koronavirusnih cjepiva BNT162b2 i Ad26.CoV2.S na proupalne i koagulacijske pokazatelje." Doctoral thesis, University of Zagreb, School of Medicine, 2024. https://urn.nsk.hr/urn:nbn:hr:105:753928

Ivanko, Iva. "Učinak koronavirusnih cjepiva BNT162b2 i Ad26.CoV2.S na proupalne i koagulacijske pokazatelje." Doctoral thesis, University of Zagreb, School of Medicine, 2024. https://urn.nsk.hr/urn:nbn:hr:105:753928

Ivanko, I. (2024). 'Učinak koronavirusnih cjepiva BNT162b2 i Ad26.CoV2.S na proupalne i koagulacijske pokazatelje', Doctoral thesis, University of Zagreb, School of Medicine, accessed 29 December 2024, https://urn.nsk.hr/urn:nbn:hr:105:753928

Ivanko I. Učinak koronavirusnih cjepiva BNT162b2 i Ad26.CoV2.S na proupalne i koagulacijske pokazatelje [Doctoral thesis]. Zagreb: University of Zagreb, School of Medicine; 2024 [cited 2024 December 29] Available at: https://urn.nsk.hr/urn:nbn:hr:105:753928

I. Ivanko, "Učinak koronavirusnih cjepiva BNT162b2 i Ad26.CoV2.S na proupalne i koagulacijske pokazatelje", Doctoral thesis, University of Zagreb, School of Medicine, Zagreb, 2024. Available at: https://urn.nsk.hr/urn:nbn:hr:105:753928

Metadata
TitleUčinak koronavirusnih cjepiva BNT162b2 i Ad26.CoV2.S na proupalne i koagulacijske pokazatelje
Title (english)The effect of BNT162b2 and Ad26.CoV2.S coronavirus vaccines on the parameters of hemostatis and inflammation
AuthorIva Ivanko
MentorPetar Gaćina (mentor)
MentorJosipa Josipović (komentor)
Committee memberDražen Pulanić (predsjednik povjerenstva)
Committee memberRobert Likić (član povjerenstva)
Committee memberAna Boban (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
Zagreb
Defense date and country2024-05-08, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Universal decimal classification
(UDC)		616 - Pathology. Clinical medicine
Abstract
Glavni cilj ovog prospektivnog opservacijskog istraživanja bio je ispitati utjecaj mRNA BNT162b2 i vektorskog Ad26.CoV2.S cjepiva protiv SARS-CoV-2 na pokazatelje zgrušavanja i upale. Istraživanje je obuhvatilo 87 ispitanika u mRNA skupini (prosječne dobi 35 god, udio žena 59% ) i 84 u vektorskoj skupini (prosječne dobi 44 godine, udio muškaraca 52%) kojima su određivani laboratorijski pokazatelji (TAT, F1+2, d-dimeri, IL-6, veliki ET-1, fibrinogen, VWF:Ac, CRP, KKS) prije, 7 i 14 dana nakon cijepljenja vektorskim, odnosno prije, 7 i 14 dana nakon 1. i 2. doze mRNA cjepiva. Nakon cijepljenja zabilježen je porast vrijednosti d-dimera (P=0,004) i pad aktivnosti VWF-a u obje skupine (P<0,001 u) te porast CRP-a (P=0,006) u vektorskoj i velikog ET-1 (P<0,001) u mRNA grupi. Veći CRP (P=0,014) zabilježen je 7 dana nakon cijepljenja vektorskim cjepivom u odnosu na mRNA cjepivo. Kod svih ispitanika isključena je prisutnost protutijela na trombociti faktor 4. Zaključno, statistički značajne razlike pokazatelja zgrušavanja i upale u našem istraživanju mogu se pripisati opće poznatoj i očekivanoj blagoj reakciji na cijepljenje SARS-CoV-2 cjepivima. Niti jedan ispitanik nije imao tromboembolijski incident u 6-mjesečnom periodu praćenja nakon cijepljenja.
Abstract (english)
The main aim of our study was to investigate the effect of mRNA BNT162b2 and vector Ad26.CoV2.S vaccine against SARS-CoV-2 on the markers of hemostasis and inflammation. The study included 87 subjects in the mRNA group (median age 35 years, 59% of women) and 84 (median age 44 years, 52% of men) in the vector group. All the laboratory parameters (TAT, F1+2, d-dimers, VWF:Ac, fibrinogen, big ET-1, CRP, CBC) were investigated before, 7 and 14 days after the vaccination in the vector group and before, 7 and 14 day after the 1st and 2nd dose in the mRNA group. After vaccination with both vaccines higher levels of d-dimers (P=0.004) and lower levels of VWF:Ac (P<0,001) were noted. CRP levels were eleveted (P=0.006) in the vector group while in the mRNA group, higer levels of big ET-1 (P<0,001) were noted. Higher CRP levels (P=0.014) were present 7 days after the vector vaccine immunisation in comparisson with the mRNA vaccine. All the study participants tested negative for platelet factor 4 antibodies. In conclusion, although statistically significant changes in the parameters of hemostatasis and inflammation have been obtained, they remained clinically irrelevant (no thromoembolic events have been noted in the 6-months surveillance period) and can be contributed to the wellknown reaction to the vaccination.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:105:753928
Study programmeTitle: Biomedicine and Health Sciences
Study programme type: university
Study level: postgraduate
Academic / professional title: doktor/doktorica znanosti, područje biomedicine i zdravstvo (doktor/doktorica znanosti, područje biomedicine i zdravstvo)
Type of resourceText
Extent96 str.
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-05-16 08:07:45